Fingerprint
Dive into the research topics of 'Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging randomized, clinical trial.'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging randomized, clinical trial.
E Suhler, Lyndell Lim, Robert Beardsley, Tracy Giles, Sirichai Pasadhika, Shelly Lee, Alexandre de Saint Sardos, Nicholas Butler, Justine Smith, James Rosenbaum
Research output: Contribution to journal › Article › peer-review
66
Citations
(Scopus)